Navigation Links
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Date:3/2/2010

A leading position in vaccines against hospital-acquired infections

Intercell expects important data from two ongoing late-stage vaccine candidates against hospital-acquired infections during 2010. If successful, we expect the Staphylococcus aureus vaccine candidate (partnered with Merck & Co., Inc.) and our Pseudomonas aeruginosa vaccine candidate to significantly contribute to the prevention of these conditions if adults and children are vaccinated on, or before, admittance to hospital.

Staphylococcus aureus vaccine (V710): Merck & Co., Inc. is developing a vaccine against S. aureus based on Intercell's antigen. Two clinical trials are ongoing in high-risk patient populations: one evaluating vaccine efficacy in patients undergoing elective cardiothoracic surgery (adaptive Phase II/III trial), and one testing immunogenicity in patients with end-stage kidney disease and receiving hemodialysis (Phase II). Intercell anticipates that interim data from the Phase II/III trial in cardiothoracic surgery patients will be available in 2010.

Pseudomonas aeruginosa vaccine: Intercell's vaccine candidate against the nosocomial infection, Pseudomonas aeruginosa, is currently being investigated in a 400-patient Phase II clinical trial. Immunogenicity and safety are being examined and first indications for t
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
2. Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
3. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
4. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
5. Iomai Stockholders Approve Merger With Intercell Subsidiary
6. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
7. RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™
8. Neogen Corporation Announces 3rd Quarter Results Conference Call
9. Raising Awareness of Rare Diseases, Anson Group Announces Sponsorship of Rare Disease Day
10. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
11. Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility ... of Product Strategy. In this role, Michelle will work with ... guide in the development of iLab products. Her main goal ... benefit to the scientific community by offering the most advanced, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Global ... developing innovative information technology solutions for patients, physicians, ... care stakeholders, announced today the signing of a ... Food and Drug Administration (FDA). This initiative ...
(Date:1/14/2014)... January 14, 2014 Kerr Corporation, a leading ... and additional how-to information about dual arch impressions on its ... Dual Arch Impressions,” the blog entry serves up a list ... houses a step-by-step demonstration by Dr. David Little as he ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... equity stake in Zenotech Laboratories to 45%, GURGAON, ... Laboratories Limited (Zenotech) today announced the,signing of Definitive Agreements, ... its current 7% to 45% at a price of ... involves: (a) Purchase of shares from the existing ...
... Monday, October 8, at 2:15 ... p.m. ... Sciences Holdings, Inc. (Nasdaq: ADLS ), a biopharmaceutical,company engaged in the ... respiratory diseases and,cancer, is scheduled to present at the Natixis Bleichroeder Hidden ...
... 3 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM ... President and Chief,Executive Officer, is scheduled to present ... 2:45pm PDT/5:45pm EDT on Wednesday, October 10. ... and can be accessed at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BIOM&item_id=1 ...
Cached Biology Technology:Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology 2Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology 3Advanced Life Sciences to Present at Natixis Bleichroeder Hidden Gems Conference 2
(Date:4/23/2014)... allergies and other chronic inflammatory disorders among people of ... their reduced exposure to the microbes that thrive in ... The article, published in the journal Clinical & ... centers who have less access to green spaces may ... caused by immune system dysfunction. , When our immune ...
(Date:4/23/2014)... This news release is available in French and ... woman? Male or female? In humans and other mammals, the difference ... Y chromosome. It is present only in males, where the two ... chromosomes. Thus, the Y is ultimately responsible for all the morphological ... not always been the case. A very long time ago, the ...
(Date:4/23/2014)... ripping open a dinner roll, a fuel cell catalyst ... hydrogen molecule. Now researchers have captured a view of ... its hydrogen feast. The view confirms previous hypotheses and ... better for alternative energy uses. , This study is ... hydrogen halves end up in the structure of a ...
Breaking Biology News(10 mins):Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3Male or female? 2Male or female? 3Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4
... in Europe and United States are markedly underestimating the ... to prevent dangerous climate change because they work in ... from The University of Manchester, discovered that the lack ... has resulted in significant differences over who is responsible ...
... An international research team has identified a common gene ... atrial fibrillation. In their report in the journal ... that variations affecting a protein that may help control the ... is called lone atrial fibrillation (AF), a type seen in ...
... Blacksburg, Va. -- Math-based computer models are a powerful ... John Tyson, professor of biology at Virginia Tech, is ... and make decisions. "Cells receive information in the ... or radiation damage, for instance," Tyson said. "On the ...
Cached Biology News:Governments 'misjudging' scale of CO2 emissions 2Common gene variant may increase risk for a type of cardiac arrhythmia 2Biologists use mathematics to advance our understanding of health and disease 2Biologists use mathematics to advance our understanding of health and disease 3
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... (Ser843) Immunogen: ... encompassing the human, mouse, and rat ... Number: NM_153831 ... by immunoblot. ...
Biology Products: